AdAlta (ASX:1AD) and its cellular immunotherapy subsidiary, AdCella, have announced a major global collaboration with Shanghai Cell Therapy Group to co-develop the first-in-class CAR-T therapy, BZDS1901, for markets outside Greater China.
This marks the official launch of AdCella's "East to West" strategy, leveraging Chinese innovation and Australian expertise to accelerate access to next-generation cellular immunotherapies.
BZDS1901 is an armored CAR-T therapy targeting mesothelin, a protein highly expressed in aggressive cancers such as mesothelioma, ovarian, lung, and pancreatic cancers.
Unlike conventional CAR-T therapies, BZDS1901 is engineered to secrete a PD1 blocker, overcoming tumor immune suppression.
Early clinical studies in China have shown promising results, including complete responses in advanced mesothelioma patients, at lower doses and with a rapid, cost-effective manufacturing process.